The Third Time’s The Charm? Xbrane Resubmits Ranibizumab In US

Follows Two Previous Knockbacks From FDA Over Lucentis Biosimilar

 
• By Dave Wallace
  
Xbrane has resubmitted its Lucentis rival to the US FDA (Shutterstock)

More from Biosimilars

More from Generics Bulletin